Insulin-like Growth Factor-I and Growth Differentiation Factor-5 Promote the Formation of Tissue-Engineered Human Nasal Septal Cartilage

被引:0
|
作者
Alexander, Thomas H. [1 ,2 ]
Sage, August B. [2 ]
Chen, Albert C. [3 ,4 ]
Schumacher, Barbara L. [2 ,3 ,4 ]
Shelton, Elliot [3 ,4 ]
Masuda, Koichi [3 ,4 ]
Sah, Robert L. [3 ,4 ]
Watson, Deborah [1 ,2 ]
机构
[1] Univ Calif San Diego, Div Otolaryngol Head & Neck Surg, San Diego, CA 92103 USA
[2] San Diego Vet Adm Med Ctr, San Diego, CA USA
[3] Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA
[4] Univ Calif San Diego, Whitaker Inst Biomed Engn, San Diego, CA 92103 USA
关键词
BONE MORPHOGENETIC PROTEIN-2; CLONAL PROLIFERATION; CELL-DENSITY; HUMAN SERUM; CHONDROCYTES; ALGINATE; PHENOTYPE; COLLAGEN; CULTURE; REDIFFERENTIATION;
D O I
10.1089/ten.tec.2009.0396
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Introduction: Tissue engineering of human nasal septal chondrocytes offers the potential to create large quantities of autologous material for use in reconstructive surgery of the head and neck. Culture with recombinant human growth factors may improve the biochemical and biomechanical properties of engineered tissue. The objectives of this study were to (1) perform a high-throughput screen to assess multiple combinations of growth factors and (2) perform more detailed testing of candidates identified in part I. Methods: In part I, human nasal septal chondrocytes from three donors were expanded in monolayer with pooled human serum (HS). Cells were then embedded in alginate beads for 2 weeks of culture in medium supplemented with 2% or 10% HS and 1 of 90 different growth factor combinations. Combinations of insulin-like growth factor-I (IGF-1), bone morphogenetic protein (BMP)-2, BMP-7, BMP-13, growth differentiation factor-5 (GDF-5), transforming growth factor beta (TGF beta)-2, insulin, and dexamethasone were evaluated. Glycosaminoglycan (GAG) accumulation was measured. A combination of IGF-1 and GDF-5 was selected for further testing based on the results of part I. Chondrocytes from four donors underwent expansion followed by three-dimensional alginate culture for 2 weeks in medium supplemented with 2% or 10% HS with or without IGF-1 and GDF-5. Chondrocytes and their associated matrix were then recovered and cultured for 4 weeks in 12mm transwells in medium supplemented with 2% or 10% HS with or without IGF-1 and GDF-5 (the same medium used for alginate culture). Biochemical and biomechanical properties of the neocartilage were measured. Results: In part I, GAG accumulation was highest for growth factor combinations including both IGF-1 and GDF-5. In part II, the addition of IGF-1 and GDF-5 to 2% HS resulted in a 12-fold increase in construct thickness compared with 2% HS alone (p < 0.0001). GAG and type II collagen accumulation was significantly higher with IGF-1 and GDF-5. Confined compression modulus was greatest with 2% HS, IGF-1, and GDF-5. Conclusion: Supplementation of medium with IGF-1 and GDF-5 during creation of neocartilage constructs results in increased accumulation of GAG and type II collagen and improved biomechanical properties compared with constructs created without the growth factors.
引用
收藏
页码:1213 / 1221
页数:9
相关论文
共 50 条
  • [41] INSULIN-LIKE GROWTH FACTOR-I STIMULATION OF LYMPHOPOIESIS
    CLARK, R
    STRASSER, J
    MCCABE, S
    ROBBINS, K
    JARDIEU, P
    JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (02): : 540 - 548
  • [42] Bioactive Insulin-Like Growth Factor-I in Obesity
    Frystyk, J.
    Brick, D. J.
    Gerweck, A. V.
    Utz, A. L.
    Miller, K. K.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (08): : 3093 - 3097
  • [43] Insulin-like growth factor-I and cancer risk
    Ibrahim, YH
    Yee, D
    GROWTH HORMONE & IGF RESEARCH, 2004, 14 (04) : 261 - 269
  • [44] SYNTHESIS OF AN INSULIN-LIKE GROWTH FACTOR-I HYBRID INSULIN
    GEIGER, R
    LANGNER, D
    HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE, 1981, 362 (06): : 799 - 807
  • [45] INSULIN-LIKE GROWTH FACTOR-I INCREASES INSULIN SENSITIVITY
    SAAD, MF
    MAALOUT, NB
    KADES, WW
    WASSILY, VM
    VITOLINS, MZ
    SEAGLE, HM
    MEEHAN, WP
    DIABETOLOGIA, 1993, 36 : A68 - A68
  • [46] THERAPEUTIC POTENTIAL OF INSULIN-LIKE GROWTH FACTOR-I
    FROESCH, ER
    GULER, HP
    SCHMID, C
    BINZ, K
    ZAPF, J
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1990, 1 (05): : 254 - 260
  • [47] EFFECTS OF INSULIN-LIKE GROWTH FACTOR-I IN MAN
    GULER, HP
    SCHMID, C
    ZAPF, J
    FROESCH, ER
    ACTA PAEDIATRICA SCANDINAVICA, 1990, : 52 - 54
  • [48] EXPRESSION OF INSULIN-LIKE GROWTH FACTOR-I IN SARCOMAS
    ROHOLL, PJM
    SKOTTNER, A
    PRINSEN, I
    LIPS, CJM
    DENOTTER, W
    VANUNNIK, JAM
    HISTOPATHOLOGY, 1990, 16 (05) : 455 - 460
  • [49] Therapeutic potential of insulin-like growth factor-I
    Ohkuma, T
    NIPPON NOGEIKAGAKU KAISHI-JOURNAL OF THE JAPAN SOCIETY FOR BIOSCIENCE BIOTECHNOLOGY AND AGROCHEMISTRY, 1998, 72 (02): : 189 - 192
  • [50] INSULIN-LIKE GROWTH FACTOR-I IN PATIENTS WITH HYPOGLYCEMIA
    LABIB, M
    TEALE, D
    MARKS, V
    ANNALS OF CLINICAL BIOCHEMISTRY, 1990, 27 : 107 - 109